Safety Profile of Medications for Allergic Rhinitis: A Meta-Epidemiological Analysis of Completed RCTs from ClinicalTrials.gov
Ivan Paladin, Mirko Maglica, Marin Gudelj, Emilija Krezo Šljivić, Franko Batinović, Darko Batistić, Shelly Melissa Pranić · 2026
Read Safety Profile of Medications for Allergic Rhinitis: A Meta-Epidemiological Analysis of Completed RCTs from ClinicalTrials.gov by Ivan Paladin, Mirko Maglica, Marin Gudelj, Emilija Krezo Šljivić, Franko Batinović, Darko Batistić, Shelly Melissa Pranić (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13210462.txt.
Description
Ivan Paladin and co-authors compare the safety of drugs for allergic rhinitis, a common allergy that inflames the nose, in work published in 2026. Treatments include nasal sprays, oral drugs, and allergy immunotherapy, each with its own risks. The team gathered safety data from completed trials listed in a public registry up to late 2023.
They included 216 trials and sorted side effects by treatment class and dose. Nasal steroid sprays were the most studied and showed the lowest rate of other side effects among spray types. Nasal antihistamine sprays caused more taste disturbance and nasal discomfort. Higher steroid doses linked to more urinary infections. Immunotherapy trials made up about a quarter of the set. The work gives clinicians a side-by-side view of harms to weigh against benefits.
Catalog record
| CREATOR | Ivan Paladin, Mirko Maglica, Marin Gudelj, Emilija Krezo Šljivić, Franko Batinović, Darko Batistić, Shelly Melissa Pranić |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |